ALS and MS Clinical Data from Clene’s CNM-Au8® Featured in Multiple Presentations at the 2023 American Academy of Neurology Annual Meeting
April 25, 2023 16:05 ET
|
Clene Inc.
SALT LAKE CITY, April 25, 2023 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage...
EnWave Signs Research and Development License Agreement with Danish Technological Institute
March 16, 2023 09:00 ET
|
EnWave Corporation
VANCOUVER, British Columbia, March 16, 2023 (GLOBE NEWSWIRE) -- EnWave Corporation (TSX-V:ENW I FSE:E4U) ("EnWave", or the "Company") today announced that it has signed a Research and Development...
Clene Reports Full Year 2022 Financial Results and Recent Operating Highlights
March 13, 2023 07:00 ET
|
Clene Inc.
Amyotrophic lateral sclerosis (ALS): Significant survival benefits demonstrated across two ALS clinical trials, along with clinical improvements as early as six months CNM-Au8® associated with 74%...
Ideal Power Reports Fourth Quarter and Full Year 2022 Financial Results
March 02, 2023 16:01 ET
|
Ideal Power Inc.
AUSTIN, Texas, March 02, 2023 (GLOBE NEWSWIRE) -- Ideal Power Inc. (“Ideal Power” or the “Company”) (Nasdaq: IPWR), pioneering the development and commercialization of the highly efficient and...
Avid Technology Announces Q4 and FY 2022 Results
March 01, 2023 16:05 ET
|
Avid Technology, Inc.
Q4 revenue of $116.1M, which includes a ($3.3M) one-time non-cash adjustment, was in the middle of the implied Q4 guidance range; excluding the adjustment, Q4 revenue of $119.4M would have been at the...
ResolutionRx Ltd and RespireRx Pharmaceuticals Inc. Announce ResolutionRx’s Entry into a Services Agreement with iNGENu CRO Pty Ltd
March 01, 2023 08:30 ET
|
RespireRX Pharmaceuticals Inc.
Glen Rock, N.J., March 01, 2023 (GLOBE NEWSWIRE) -- ResolutionRx Ltd (“ResolutionRx”), an unlisted public Australian company, (Australian Company Number or ACN: 664 925 651, Australian Business...
Clene Announces Updated VISIONARY-MS Phase 2 Trial Data Presented at 2023 ACTRIMS Forum Show CNM-Au8® Demonstrated Significant Improvements in Clinical Outcomes, Brain Structure, and Visual System
February 27, 2023 07:00 ET
|
Clene Inc.
Positive clinical results demonstrated in stable relapsing multiple sclerosis patients adjunctive to immunomodulatory disease modifying therapy was previously reportedUpdated Visual Evoked Potential...
Clene Reports New Data from the VISIONARY-MS Phase 2 Study in Multiple Sclerosis Demonstrating CNM-Au8® Treatment Improved Brain Neuronal Structural Integrity
February 13, 2023 07:00 ET
|
Clene Inc.
MRI results reinforce the clinical neurological improvements previously reportedMRI results showed improved brain neuronal structural integrity, independent of an immunomodulatory effectMRI results...
ResolutionRx Ltd, a wholly owned subsidiary of RespireRx Pharmaceuticals Inc. Enters into LOI and Term Sheet with Radium Capital for the financing of anticipated Research and Development Credits
February 01, 2023 08:30 ET
|
RespireRX Pharmaceuticals Inc.
Glen Rock, N.J., Feb. 01, 2023 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTC Markets: RSPI) (“RespireRx” or the “Company”), a leader in the discovery and development of innovative and...
Ideal Power Reports Third Quarter 2022 Financial Results
November 14, 2022 16:05 ET
|
Ideal Power Inc.
AUSTIN, Texas, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Ideal Power Inc. (“Ideal Power” or the “Company”) (Nasdaq: IPWR), pioneering the development and commercialization of the highly efficient and...